Skip to content
Search

Latest Stories

NICE recommends abemaciclib for early breast cancer

The National Institute for Health and Care Excellence (NICE) has recommended abemaciclib also called Verzenios, made by Eli Lilly, for people with hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence who have had surgery to remove their tumour.

The clinical trial result showed that people having abemaciclib with hormone therapy had a more than 30 per cent better chance of their cancer not coming back following surgery compared with people having hormone therapy alone.


Helen Knight, interim director of medicines evaluation at NICE, said: “Today’s positive draft recommendation, which comes less than a month after abemaciclib received its licence, is fantastic news. The fact that we have been able to produce draft recommendations so quickly is testament to the success of our ambition to support patient access to clinically and cost effective treatments as early as possible.

“Until now there have been no targeted treatments for people with this type of breast cancer. Abemaciclib with hormone therapy represents a significant improvement in how it is treated because being able to have a targeted treatment earlier after surgery will increase the chance of curing the disease and reduce the likelihood of developing incurable advanced disease.”

Professor Peter Johnson, National Clinical Director for Cancer for NHS England, said: “Thanks in part to this latest deal struck by NHS England, NHS patients will be able to access another new targeted drug for a common and aggressive form of breast cancer.

“Abemaciclib, when used alongside a hormone therapy, offers a new doubly targeted treatment option, helping to increase the chances of beating the cancer for good, as well as meeting the NHS’ commitment to delivering improved cancer care under our Long Term Plan.”

Treatment with chemotherapy or hormone therapy, or both, has remained the standard of care for many years for people with hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence following surgery.

Around 50,000 people a year are diagnosed in England with breast cancer. HER2-negative breast cancer is the most common type, accounting for about 70 per cent of all breast cancers. It is estimated that early breast cancer comes back after initial treatment in around 30 per cent of people.

More For You

The Complete Anti-Inflammatory Guide - a useful resource for pharmacists to support patient health and wellbeing

Chronic inflammation is linked to more than 50 per cent of all deaths worldwide and one in five cancers.

The Complete Anti-Inflammatory Guide - a useful resource for pharmacists to support patient health and wellbeing

When Hemant Patel was struck down by Covid, he was determined to discover what was it that led to the disease having a devastating impact on the lives of people who seemed be healthy – the culmination of his journey is the book, The Complete Anti-Inflammatory Guide.

“I was gasping for breath and counting the number of days I might be alive when I was infected with Covid,” reveals Patel.

Keep ReadingShow less
Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less